Related Experiment Videos
[Hairy cell leukemia therapy by cladribine]
1Department of Hematology and Cell Therapy, Aichi Cancer Center.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 31, 2004
Summary
Cladribine (2-chlorodeoxyadenosine: 2-CdA) is a safe and effective purine analog treatment for hairy cell leukemia (HCL). This review covers its structure, efficacy, safety, and approved indications for HCL therapy.
Area of Science:
- Oncology
- Pharmacology
Context:
- Hairy cell leukemia (HCL) is a rare B-cell chronic lymphoid leukemia.
- Effective and safe therapeutic options are crucial for managing symptomatic HCL.
Purpose:
- To review the structure, mechanism of action, and clinical data of cladribine (2-chlorodeoxyadenosine: 2-CdA).
- To discuss the efficacy and safety of 2-CdA as a first-choice treatment for HCL.
- To outline the indications for cladribine therapy in HCL patients.
Summary:
- Cladribine (2-CdA), a purine nucleoside analog, is an approved and highly effective treatment for hairy cell leukemia.
- It is administered intravenously at 0.09 mg/kg daily for 7 days.
- The review encompasses 2-CdA's structure, mechanism, clinical efficacy, safety, and therapeutic indications.
Impact:
- Cladribine provides a well-established, safe, and effective therapeutic option for patients with hairy cell leukemia.
- Understanding its profile supports optimal clinical decision-making in HCL management.
- Highlights the significance of cladribine as a first-line therapy in approved regions.